News
8m
News-Medical.Net on MSNImproving RNA drug delivery through intracellular traffic controlA recent study involving researchers from the University of Basel reveals that slowing down the intracellular transport of ...
Family fears losing Medicaid coverage, which they rely on for life-saving care. They face uncertainty due to new work ...
New consensus guidelines outline best practices for orthopedic management in Duchenne muscular dystrophy, focusing on ...
In one of the first major tests of the new FDA leadership’s regulatory philosophy toward gene therapies for rare diseases, ...
Sarepta Therapeutics Inc. misled investors about the safety and prospects for one of its Duchenne muscular dystrophy ...
One visit to Virginia Peninsula Community College’s Historic Triangle Campus last summer eased any concerns they might have had. Soon after entering the building, Nicholas and his mother, Liz, were ...
Edgewise Therapeutics (NASDAQ:EWTX) lost ~9% in the morning hours on Thursday after the company posted data from clinical ...
The FDA found that data from a single Phase II study were “insufficient” to justify an accelerated approval review for ...
The FDA said yesterday that it is investigating the deaths from liver failure of two non-ambulatory boys with Duchenne ...
14h
Irish Examiner on MSNCouple push for drug that slows down muscular dystrophy to be made available in IrelandThe drug Givinostat has been brought into parts of Britain. We want that too, but we need the government to pay for it,' said Una Ennis ...
Duchenne muscular dystrophy families are sharing stories about Elevidys complications on social media. But they aren’t ...
Edgewise reports sustained functional stability in Becker patients and selects Phase 3 dose for Duchenne after positive Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results